- Current report filing (8-K)
March 07 2011 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of Earliest event Reported): March 7, 2011
CHINA BIOLOGIC PRODUCTS,
INC.
(Exact name of registrant as specified in its
charter)
Delaware
|
001-34566
|
75-2308816
|
(State or other jurisdiction of
|
(Commission File No.)
|
(IRS Employer ID No.)
|
incorporation or organization)
|
|
|
|
|
|
|
No. 14 East Hushan Road,
|
|
|
Tai'an City, Shandong, 271000
|
|
|
People's Republic of China
|
|
|
(Address of Principal Executive Offices)
|
|
|
|
|
|
86-538 -620-2306
|
|
Registrant's telephone number, including area
code
|
|
|
(Former name or former address, if changed since last
report)
|
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General Instruction A.2. below):
[ ] Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
Item 7.01 Regulation FD Disclosure.
In connection with the distribution of presentation materials
by China Biologic Products, Inc. (the "Company") at the Annual China Investment
Conference held by Rodman & Renshaw (the "Rodman Conference") and in
anticipation of the planned presentations at the Rodman Conference and the 31st
Annual Healthcare Conference held by Cowen and Company, LLC (the "Cowen
Conference," and together with the Rodman Conference, the "Conferences") and the
distribution of materials at the Cowen Conference, the Company is furnishing the
information contained in this current report on Form 8-K in order to avoid the
selective disclosure of any material nonpublic information at the Conferences.
The Companys presentation materials are attached hereto as Exhibits 99.1.
The information contained in this Current Report on Form 8-K
and the exhibits attached hereto shall not be deemed to be "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section, nor shall such
information or such exhibits be deemed incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing. The
information set forth in or exhibits to this Form 8-K shall not be deemed an
admission as to the materiality of any information in this report on Form 8-K
that is required to be disclosed solely to satisfy the requirements of
Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date: March 7, 2011
|
CHINA
BIOLOGIC PRODUCTS, INC.
|
|
|
|
|
By:
|
/s/ Chao Ming Zhao
|
|
|
Chao Ming Zhao
|
|
|
Chief Executive Officer
|
|
|
|
|
|
|
3
EXHIBIT INDEX
4
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jun 2024 to Jul 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Jul 2023 to Jul 2024